source
- FDA launches Rare Disease Framework to embed patient input early in drug developmentFDA's Center for Biologics Research and Evaluation (CBER) director Karim Mikhail announced a new Rare Disease Framework Initiative aimed at moving patient perspectives from an optional, late‑stage…
- Argenx acquires Unnatural Products for up to $1.15 billion to boost oral peptide platformArgenx announced it will buy biotech Unnatural Products, paying $550 million upfront with the total deal value potentially reaching $1.15 billion through development and regulatory milestones. The…